Hong Kong Medical Equipment Supplier Powei Pharma (AED.US) Files for US IPO, Aims to Raise $7 Million

Stock News12-15

Powei Pharma (AED.US), a Hong Kong-based medical equipment and software procurement company, filed with the U.S. Securities and Exchange Commission (SEC) last Thursday for an initial public offering (IPO) to raise up to $7 million. The company plans to issue 900,000 shares priced between $7 and $9 per share, targeting a $7 million capital raise. At the midpoint of the proposed price range, Powei Pharma would have a market valuation of $87 million.

Through its subsidiaries, Powei Pharma distributes medical devices and software to healthcare providers and distributors in Hong Kong and mainland China. Its product portfolio includes infusion pumps, anesthesia laryngoscopes, portable X-ray machines, automated external defibrillators, and proprietary medical software such as Prim (a preclinical imaging post-processing tool) and iMRIPlus (an MRI analysis platform).

Founded in 2003, the Hong Kong-headquartered company reported $25 million in revenue for the 12-month period ending March 31, 2025. Powei Pharma intends to list on the Nasdaq under the ticker symbol "AED," with Maxim Group LLC serving as the sole bookrunner for the offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156537236?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156537236","market":"other","top_or_hot":-1,"title":"Hong Kong Medical Equipment Supplier Powei Pharma (AED.US) Files for US IPO, Aims to Raise $7 Million","media":"Stock News","content":"<p>Powei Pharma (AED.US), a Hong Kong-based medical equipment and software procurement company, filed with the U.S. Securities and Exchange Commission (SEC) last Thursday for an initial public offering (IPO) to raise up to $7 million. The company plans to issue 900,000 shares priced between $7 and $9 per share, targeting a $7 million capital raise. At the midpoint of the proposed price range, Powei Pharma would have a market valuation of $87 million.</p>\n<p>Through its subsidiaries, Powei Pharma distributes medical devices and software to healthcare providers and distributors in Hong Kong and mainland China. Its product portfolio includes infusion pumps, anesthesia laryngoscopes, portable X-ray machines, automated external defibrillators, and proprietary medical software such as Prim (a preclinical imaging post-processing tool) and iMRIPlus (an MRI analysis platform).</p>\n<p>Founded in 2003, the Hong Kong-headquartered company reported $25 million in revenue for the 12-month period ending March 31, 2025. Powei Pharma intends to list on the Nasdaq under the ticker symbol \"AED,\" with Maxim Group LLC serving as the sole bookrunner for the offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Medical Equipment Supplier Powei Pharma (AED.US) Files for US IPO, Aims to Raise $7 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Medical Equipment Supplier Powei Pharma (AED.US) Files for US IPO, Aims to Raise $7 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Powei Pharma (AED.US), a Hong Kong-based medical equipment and software procurement company, filed with the U.S. Securities and Exchange Commission (SEC) last Thursday for an initial public offering (IPO) to raise up to $7 million. The company plans to issue 900,000 shares priced between $7 and $9 per share, targeting a $7 million capital raise. At the midpoint of the proposed price range, Powei Pharma would have a market valuation of $87 million.</p>\n<p>Through its subsidiaries, Powei Pharma distributes medical devices and software to healthcare providers and distributors in Hong Kong and mainland China. Its product portfolio includes infusion pumps, anesthesia laryngoscopes, portable X-ray machines, automated external defibrillators, and proprietary medical software such as Prim (a preclinical imaging post-processing tool) and iMRIPlus (an MRI analysis platform).</p>\n<p>Founded in 2003, the Hong Kong-headquartered company reported $25 million in revenue for the 12-month period ending March 31, 2025. Powei Pharma intends to list on the Nasdaq under the ticker symbol \"AED,\" with Maxim Group LLC serving as the sole bookrunner for the offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1156537236","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156537236","pubTimestamp":1765789220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Powei Pharma (AED.US), a Hong Kong-based medical equipment and software procurement company, filed with the U.S. Securities and Exchange Commission (SEC) last Thursday for an initial public offering...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159873":"医疗设备","159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"香港医疗设备供应商破维制药(AED.US)申请赴美IPO，拟募资700万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159873":1,"159938":1,"09939":1},"content_text":"Powei Pharma (AED.US), a Hong Kong-based medical equipment and software procurement company, filed with the U.S. Securities and Exchange Commission (SEC) last Thursday for an initial public offering (IPO) to raise up to $7 million. The company plans to issue 900,000 shares priced between $7 and $9 per share, targeting a $7 million capital raise. At the midpoint of the proposed price range, Powei Pharma would have a market valuation of $87 million.\nThrough its subsidiaries, Powei Pharma distributes medical devices and software to healthcare providers and distributors in Hong Kong and mainland China. Its product portfolio includes infusion pumps, anesthesia laryngoscopes, portable X-ray machines, automated external defibrillators, and proprietary medical software such as Prim (a preclinical imaging post-processing tool) and iMRIPlus (an MRI analysis platform).\nFounded in 2003, the Hong Kong-headquartered company reported $25 million in revenue for the 12-month period ending March 31, 2025. Powei Pharma intends to list on the Nasdaq under the ticker symbol \"AED,\" with Maxim Group LLC serving as the sole bookrunner for the offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156537236","isCrawlerRequest":true}